Direkt zum Inhalt
Merck

P0069

Sigma-Aldrich

PRIMA-1

≥98% (HPLC), solid

Synonym(e):

2,2-Bishydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C9H15NO3
CAS-Nummer:
Molekulargewicht:
185.22
MDL-Nummer:
UNSPSC-Code:
12352200
PubChem Substanz-ID:
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

solid

Farbe

white to off-white

Löslichkeit

H2O: >10 mg/mL

Lagertemp.

2-8°C

SMILES String

OCC1(CO)N2CC[C@@H](CC2)C1=O

InChI

1S/C9H15NO3/c11-5-9(6-12)8(13)7-1-3-10(9)4-2-7/h7,11-12H,1-6H2

InChIKey

RFBVBRVVOPAAFS-UHFFFAOYSA-N

Allgemeine Beschreibung

P53-dependent reactivation and induction of massive apoptosis (PRIMA-1) is a low molecular weight compound and has a role in cancer therapy. PRIMA-1 stimulates cytotoxic effects in human cancer cells. It induces eryptosis.

Biochem./physiol. Wirkung

PRIMA-1 is a selective re-activator of mutant p53 activity in tumor cells, and an inducer of apoptosis and inhibitor of growth of human tumors with mutant p53. Mutations in the tumor suppressor p53 take place in >50% tumor cells. PRIMA-1 selectively restores sequence-specific DNA binding and transactivational activity to mutant p53 proteins at μM concentrations. PRIMA-1 works as a re-activator of the apoptotic function of mutant p53 via conformational modulation of function-specific epitopes.

Piktogramme

Health hazardExclamation mark

Signalwort

Danger

H-Sätze

Gefahreneinstufungen

Acute Tox. 4 Oral - Resp. Sens. 1

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi H, et al.
British Journal of Haematology, 127(3), 285-291 (2004)
PRIMA-1 as a cancer therapy restoring mutant p53: A review
Lewis EJ
Bioscience Horizons, 8 (2015)
Masashi Idogawa et al.
Oncotarget, 5(17), 7540-7548 (2014-10-04)
p53 transduction is a potentially effective cancer therapy but does not result in a good therapeutic response in all human cancers due to resistance to apoptosis. To discover factors that overcome resistance to p53-induced apoptosis, we attempted to identify RNAi
Stimulation of suicidal erythrocyte death by PRIMA-1
Faggio C, et al.
Cellular Physiology and Biochemistry, 35(2), 529-540 (2015)
Federica Eduati et al.
Molecular systems biology, 16(2), e8664-e8664 (2020-02-20)
Mechanistic modeling of signaling pathways mediating patient-specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating such models for patients, in particular for solid malignancies, is challenging. A major hurdle to build these models

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.